VeraMorph is a pre-clinical strategic pharmaceutical company driven by the mission of prolonging and improving patient lives by maximizing the therapeutic potential of any and all therapeutic drug substances with our oral drug delivery platform. VeraMorph was founded in 2017 by an MIT post-doc with a vision of applying advanced materials and chemical engineering principles to improve human health. We've since expanded into a lean corporation supported by federal grants and external investors accelerating the development of clinically differentiated drug products that will improve patient outcomes.
Patient-focused product design to maximize quality of life
R&D efficiency to commercialize affordable therapies
Scientific rigor to ensure products of the highest quality
Innovation to improve upon standard of care
A culture of humility and teamwork to consider all perspectives
VeraMorph is a lean specialty pharmaceutical company leveraging internal expertise in materials science, pharmaceutical formulation, and process chemistry to efficiently develop high value, clinically differentiated drug products leveraging our platform oral drug delivery technology, while leveraging the capabilities of commercialization partners to bring those products to market in a cost-effective, accelerated timeline.
VeraMorph is creating value through the development of both a portfolio of patent-protected oral drug products and out-licensing of our platform technology to pharmaceutical partners developing novel drug products across several disease areas. This approach diversifies revenue streams in such a way that optimizes the balance of maximizing value creation while minimizing associated regulatory and clinical risk for shareholders.